No Data
No Data
Vanda Pharmaceuticals' Earnings Call: Mixed Results and Future Optimism
Vanda Pharmaceuticals | 10-K: Annual report
Cantor Fitzgerald Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $13
Vanda Pharmaceuticals Sees Revenue Growth Amid Strategic Expansions
Earnings Call Summary | Vanda Pharmaceuticals(VNDA.US) Q4 2024 Earnings Conference
Vanda Pharmaceuticals Targets Total Annual Revenue in Excess of $1B in 2030